-Reuters
Raymond James Beefs Up UnitedHealth Price Target On Smoother Sailing Of Change Deal
Raymond James reiterates a Strong Buy rating on UnitedHealth Group Inc (NYSE:UNH) while raising the price target to $635 from $620 as…
U.S. House Of Representatives Backs Record $858B Defense Authorization Bill, Voting Continues
-Reuters
Related Posts
Novo Nordisk’s Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Novo Nordisk's application for once-weekly insulin icodec on May 24. Concerns include an increased risk of hypoglycemia in type 1 diabetes patients.
Amphenol Q2 Highlights: Earnings Beat, 3% Revenue Dip, Warning On Ongoing Challenges & More
Amphenol Corporation (NYSE: APH) reported a second-quarter FY23 sales decline of 2.6% year-on-year to $3.054 billion,
Jefferies Maintains Buy on Provention Bio, Raises Price Target to $15
Jefferies analyst Chris Howerton maintains Provention Bio (NASDAQ:PRVB) with a Buy and raises the price target from $10 to $15.